Videos

At Great Debates and Updates in Women’s Oncology, Laura Huppert, MD, argued that routine screening for brain metastases is unnecessary for patients with either early or metastatic HER2-positive breast cancer.

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that pemetrexed maintenance therapy should eventually be stopped.

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that continuing pemetrexed maintenance therapy is advantageous for patients treated with the KEYNOTE-189 regimen.

Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.

At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic breast cancer.

At the 2024 Great Debates and Updates in Women’s Oncology meeting, Ying Liu, MD, MPH, makes an argument for platinum-based chemotherapy as the optimal treatment for patients with platinum-sensitive recurrent ovarian cancer.

At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.

At Great Debates and Updates in Women’s Oncology, Neil Iyengar, MD, discusses the lack of data to support the sequential use of antibody drug conjugates for patients with metastatic breast cancer.

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that upfront liquid biopsies are an essential part of the initial patient workup.

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that perioperative immunotherapy should not be used to treat patients with lung cancer.